Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Editas Medicine Inc shares valued at $1,774 were sold by Mei Baisong on Sep 04 ’24. At $3.42 per share, Mei Baisong sold 518 shares. The insider’s holdings dropped to 133,895 shares worth approximately $0.39 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, O’Neill Gilmore Neil sold 1,555 shares, netting a total of over 5,325 in proceeds. Following the sale of shares at $3.42 each, the insider now holds 313,724 shares.
Before that, O’Neill Gilmore Neil had added 3,000 shares to its account. In a trade valued at $11,760, the Officer bought Editas Medicine Inc shares for $3.92 each.
As published in a research note from BofA Securities on August 08, 2024, Editas Medicine Inc [EDIT] has been rated up from a Neutral to a Buy and the price target has been revised to $15 from $13. Analysts at Morgan Stanley upgraded the stock from ‘”an Underweight”‘ to ‘”an Equal-weight”‘ outlook in a report released in early May. As of October 24, 2023, Citigroup has increased its “Neutral” rating to a “Buy” for EDIT. Earlier on October 18, 2023, JP Morgan upgraded its rating. Their new recommendation was “a Neutral” for EDIT stock which previously was a “an Underweight”.
Analyzing EDIT Stock Performance
During the last five days, there has been a drop of approximately -8.81%. Over the course of the year, Editas Medicine Inc shares have dropped approximately -71.37%. Shares of the company reached a 52-week high of $11.58 on 02/28/24 and a 52-week low of $2.90 on 10/31/24. A 50-day SMA is recorded $3.48, while a 200-day SMA reached $5.57. Nevertheless, trading volume fell to 1.96 million shares from 1.69 million shares the previous day.
Support And Resistance Levels for Editas Medicine Inc (EDIT)
According to the 24-hour chart, there is a support level at 2.86, which, if violated, would cause prices to drop to 2.81. In the upper region, resistance lies at 2.99. The next price resistance is at 3.07. RSI (Relative Strength Index) is 37.08 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.25, which suggests the price will decrease in the coming days. Percent R is at 100.00%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
